Editorial Material
Urology & Nephrology
Matthew S. Ernst, Vishal Navani, J. Connor Wells, Frede Donskov, Naveen Basappa, Chris Labaki, Sumanta K. Pal, Luis Meza, Lori A. Wood, D. Scott Ernst, Bernadett Szabados, Rana R. McKay, Francis Parnis, Cristina Suarez, Takeshi Yuasa, Aly-Khan Lalani, Ajjai Alva, Georg A. Bjarnason, Toni K. Choueiri, Daniel Y. C. Heng
Summary: This study establishes real-world clinical benchmarks for immune-oncology (IO) and vascular endothelial growth factor targeted therapies (VEGF-TT) combination treatments in metastatic renal cell carcinoma (mRCC) patients, based on the International mRCC Database Consortium (IMDC) criteria.
Article
Oncology
Jorg Beyer, Laurence Collette, Nicolas Sauve, Gedske Daugaard, Darren R. Feldman, Torgrim Tandstad, Alexey Tryakin, Olof Stahl, Enrique Gonzalez-Billalabeitia, Ugo De Giorgi, Stephane Culine, Ronald de Wit, Aaron R. Hansen, Marko Bebek, Angelika Terbuch, Costantine Albany, Marcus Hentrich, Jourik A. Gietema, Helene Negaard, Robert A. Huddart, Anja Lorch, Fay H. Cafferty, Daniel Y. C. Heng, Christopher J. Sweeney, Eric Winquist, Michal Chovanec, Christian Fankhauser, Daniel Stark, Peter Grimison, Andrea Necchi, Ben Tran, Axel Heidenreich, Jonathan Shamash, Cora N. Sternberg, David J. Vaughn, Ignacio Duran, Carsten Bokemeyer, Anna Patrikidou, Richard Cathomas, Samson Assele, Silke Gillessen
Summary: The classification of IGCCCG has been a major advancement in the management of germ-cell tumors, but a modern series of 2,451 men with metastatic seminoma treated between 1990 and 2013 showed significant improvement in progression-free survival and overall survival compared to the original data. The original IGCCCG classification remains relevant, but can be further refined by adding LDH at a cutoff of 2.5x upper limit of normal as an additional adverse prognostic factor.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Urology & Nephrology
Jennifer M. King, Sandra Althouse, Clint Cary, Timothy Masterson, Richard S. Foster, Ryan Ashkar, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra
Summary: This study reports the long-term outcomes of patients with metastatic germ cell tumors who achieved a complete response (CR) after first-line chemotherapy. The majority of patients had no evidence of disease during the follow-up period, and patients in the good risk category had a higher survival rate.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Luca Antonelli, Davide Ardizzone, Praful Ravi, Aditya Bagrodia, Michal Mego, Siamak Daneshmand, Nicola Nicolai, Sebastiano Nazzani, Patrizia Giannatempo, Andrea Franza, Axel Heidenreich, Pia Paffenholz, Ragheed Saoud, Scott Eggener, Matthew Ho, Nathaniel Oswald, Kathleen Olson, Alexey Tryakin, Mikhail Fedyanin, Natacha Naoun, Christophe Javaud, Karim Fizazi, Jennifer M. King, Nabil Adra, Antoin Douglawi, Clint Cary, Christopher Sweeney, Christian D. Fankhauser
Summary: This study analyzed the proportion of residual teratoma and survival among patients with intermediate/poor prognosis after first-line chemotherapy. The results showed that most patients relapsed only in the retroperitoneum after undergoing surgery, and there was no significant difference in overall survival between the two groups.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Urology & Nephrology
David Lorente, Casilda Llacer, Rebeca Lozano, Guillermo de Velasco, Nuria Romero-Laorden, Miguel Rodrigo, Angel Sanchez-Iglesias, Carlos di Capua, Elena Castro, Carlos Ferrer, Alfredo Sanchez-Hernandez, David Olmos
Summary: This study validated the prognostic value of the Armstrong risk model in patients treated with first-line androgen receptor signaling inhibitors, showing that low-risk patients received the greatest benefit. Further research is needed to establish the role of Armstrong risk groups for treatment selection in mCRPC patients.
Article
Oncology
Gaia Giannone, Daniele Castaldo, Valentina Tuninetti, Giulia Scotto, Margherita Turinetto, Anna Amela Valsecchi, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Summary: The survey conducted among Italian MITO centers showed that while doctors have good knowledge of diagnostic and therapeutic innovations in EC, these innovations are not fully implemented in everyday clinical practice, except for the assessment of MSI status.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander Spira, Daniel C. Cho, Shanhong Guan, Erika Puente, Tuan Nguyen, Ute Hoch, Sue L. Currie, Wei Lin, Mary A. Tagliaferri, Jonathan Zalevsky, Mario Sznol, Michael E. Hurwitz
Summary: This study found that the combination of BEMPEG and NIVO showed promising antitumor activity in first-line metastatic melanoma, including extended median progression-free survival. Early on-treatment blood biomarkers were associated with treatment response.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Marcus Hentrich, Jessica Debole, Vindi Jurinovic, Arthur Gerl
Summary: The treatment of metastatic germ cell cancer is based on the 1997 IGCCCG prognostic classification, with improved outcomes over time. Excellent prognosis was seen in intermediate-risk patients, but treatment improvement is needed for those in the poor-prognosis group.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Luca Ielasi, Francesco Tovoli, Matteo Tonnini, Bernardo Stefanini, Raffaella Tortora, Giulia Magini, Rodolfo Sacco, Tiziana Pressiani, Franco Trevisani, Ingrid Garajova, Fabio Piscaglia, Alessandro Granito
Summary: This study aimed to evaluate the prognostic role of different sites of metastases in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. The results showed that lymph nodes and lung metastases were associated with worse survival rates and treatment response, while bone and adrenal gland metastases did not significantly impact prognosis. Therefore, targeted treatment strategies should be considered for different metastatic sites.
Article
Oncology
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, Giulia Scotto, Valentina Tuninetti, Margherita Turinetto, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Vera Loizzi, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Summary: A better understanding of the molecular features of EC has led to a new era of immunotherapy, providing alternative treatment approaches even for advanced cases.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Bryce R. Christensen, Yasmin M. Hajja, Vadim Koshkin, Pedro C. Barata
Summary: The treatment for metastatic renal cell carcinoma has evolved significantly in recent years, with options including local therapy, active surveillance, and targeted therapy. Combination regimens with ICI are the most effective and ongoing studies aim to optimize treatment selection for personalized disease management.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Nutrition & Dietetics
Mark Stares, Amanda Swan, Kirsten Cumming, Tze-En Ding, James Leach, Cory Stratton, Findlay Thomson, Colin Barrie, Kirsty MacLennan, Sorcha Campbell, Tamasin Evans, Aisha Tufail, Stephen Harrow, Melanie MacKean, Iain Phillips
Summary: Albumin is a reliable prognostic factor in patients with metastatic NSCLC, predicting survival independent of the class of drug treatment at various time points during the patient journey. Tracking albumin concentrations during systemic therapy may indicate disease activity or treatment response over time.
FRONTIERS IN NUTRITION
(2021)
Article
Oncology
Ah Reum Lim, Jwa Hoon Kim, Myung Han Hyun, Yeul Hong Kim, Soohyeon Lee
Summary: This study investigated the changes in renal function among mCRC patients who received first-line chemotherapy and analyzed the prognostic factors and the effect of each chemotherapy regimen on renal function. The study found that renal function significantly decreased after 12 months of chemotherapy, with FOLFIRI + bevacizumab causing more frequent renal dysfunction. Older age, lower BMI, and baseline proteinuria were also associated with decreased renal function.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Urology & Nephrology
Christian Daniel Fankhauser, Ben Tran, Manuel Pedregal, Jose Manuel Ruiz-Morales, Egon Gonzalez-Billalabeitia, Anna Patrikidou, Eitan Amir, Christoph Seidel, Carsten Bokemeyer, Thomas Hermanns, Alexey Rumyantsev, Alexey Tryakin, Margarida Brito, Aude Flechon, Edmon M. Kwan, Tina Cheng, Daniel Castellano, Xavier Garcia Del Muro, Anis A. Hamid, Margaret Ottaviano, Giovanella Palmieri, Robert Kitson, Alison Reid, Daniel Y. C. Heng, Philippe L. Bedard, Christopher J. Sweeney, Jean M. Connors
Summary: The study evaluated the role of prophylactic anticoagulation in preventing VTE in patients with metastatic germ cell tumors (mGCTs), finding that avoiding the use of venous access devices and carefully selecting appropriate prophylactic anticoagulation can reduce the risk of VTE occurring during chemotherapy.
EUROPEAN UROLOGY FOCUS
(2021)
Article
Oncology
Furqan Shaikh, Daniel Stark, Adriana Fonseca, Ha Dang, Caihong Xia, Mark Krailo, Farzana Pashankar, Carlos Rodriguez-Galindo, Thomas A. Olson, James C. Nicholson, Matthew J. Murray, James F. Amatruda, Deborah Billmire, Sara Stoneham, A. Lindsay Frazier
Summary: Adolescent patients with metastatic GCTs have clinical characteristics more similar to young adult patients than children. The event-free survival (EFS) for adolescents is worse than that for children but similar to young adults. Coordination of initiatives across clinical trial organizations is crucial to improve outcomes for adolescents and young adults.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)